INSM Stock Up 17% after 6-Day Win Streak
Insmed (INSM) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 17% return. The company has gained about $4.1 Bil in value over the last 6 days, with its current market capitalization at about $24 Bil. The stock remains 85.1% above its value at the end of 2024. This compares with year-to-date returns of 9.7% for the S&P 500.
INSM provides therapies for serious, rare diseases, including ARIKAYCE for Mycobacterium avium complex lung disease and developing Brensocatib, an oral inhibitor targeting dipeptidyl peptidase 1. After this rally, is INSM still a buy – or is it time to lock in gains? Deep dive with Buy or Sell INSM.
Comparing INSM Stock Returns With The S&P 500
The following table summarizes the return for INSM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | INSM | S&P 500 |
|---|---|---|
| 1D | 0.0% | -0.3% |
| 6D (Current Streak) | 16.9% | 1.7% |
| 1M (21D) | 22.7% | 2.4% |
| 3M (63D) | 90.1% | 9.0% |
| YTD 2025 | 85.1% | 9.7% |
| 2024 | 122.8% | 23.3% |
| 2023 | 55.1% | 24.2% |
| 2022 | -26.7% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has INSM behaved after prior drops? See INSM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 24 |
| 4D | 16 | 2 |
| 5D | 4 | 0 |
| 6D | 1 | 1 |
| 7D or more | 5 | 0 |
| Total >=3 D | 35 | 27 |
Key Financials for Insmed (INSM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $305.2 Mil | $363.7 Mil |
| Operating Income | $-680.9 Mil | $-786.6 Mil |
| Net Income | $-749.6 Mil | $-913.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $92.8 Mil | $107.4 Mil |
| Operating Income | $-229.8 Mil | $-253.9 Mil |
| Net Income | $-256.6 Mil | $-321.7 Mil |
While INSM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.